PURPOSE: To characterise the gastrointestinal toxicities associated with Trastuzumab administration in HER2-overexpressing breast cancer patients. METHODS: All patients (n = 46) who received Trastuzumab as a single agent or in conjunction with conventional anti-cancer treatment within the Royal Adelaide Hospital Cancer Centre from 2002-2007 were included in this study. A retrospective analysis of case-notes was conducted to investigate the toxicities associated with Trastuzumab. RESULTS: Trastuzumab as a single agent induced toxicities following 22% of administrations. Gastrointestinal toxicities were observed following 12% of administrations and included nausea and vomiting, diarrhoea, abdominal pain and bloating. However, other prominent toxicities that were not related to the gastrointestinal tract were also observed including fatigue and lung symptoms (10.4%). Elderly patients (> or =60 years) and those with metastatic disease experienced the highest frequency of toxicity. CONCLUSION: Trastuzumab induces a range of gastrointestinal toxicities in HER2-overexpressing breast cancer patients. These toxicities are separate to those caused by concurrent chemotherapy and/or radiotherapy.
PURPOSE: To characterise the gastrointestinal toxicities associated with Trastuzumab administration in HER2-overexpressing breast cancerpatients. METHODS: All patients (n = 46) who received Trastuzumab as a single agent or in conjunction with conventional anti-cancer treatment within the Royal Adelaide Hospital Cancer Centre from 2002-2007 were included in this study. A retrospective analysis of case-notes was conducted to investigate the toxicities associated with Trastuzumab. RESULTS:Trastuzumab as a single agent induced toxicities following 22% of administrations. Gastrointestinal toxicities were observed following 12% of administrations and included nausea and vomiting, diarrhoea, abdominal pain and bloating. However, other prominent toxicities that were not related to the gastrointestinal tract were also observed including fatigue and lung symptoms (10.4%). Elderly patients (> or =60 years) and those with metastatic disease experienced the highest frequency of toxicity. CONCLUSION:Trastuzumab induces a range of gastrointestinal toxicities in HER2-overexpressing breast cancerpatients. These toxicities are separate to those caused by concurrent chemotherapy and/or radiotherapy.
Authors: Maurizio Tonato; Rebecca A Clark-Snow; David Osoba; Albano Del Favero; Enzo Ballatori; Sussanne Borjeson Journal: Support Care Cancer Date: 2004-11-18 Impact factor: 3.603
Authors: Hu Xu; Yingjie Yu; Dorota Marciniak; Arun K Rishi; Fazlul H Sarkar; Omer Kucuk; Adhip P N Majumdar Journal: Mol Cancer Ther Date: 2005-03 Impact factor: 6.261
Authors: Shari A Price-Schiavi; Eran Andrechek; Nebila Idris; Peter Li; Min Rong; Jin Zhang; Coralie A Carothers Carraway; William J Muller; Kermit L Carraway Journal: J Cell Physiol Date: 2005-04 Impact factor: 6.384
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard Pietras; Dennis J Slamon Journal: J Natl Cancer Inst Date: 2004-05-19 Impact factor: 13.506
Authors: Ian Olver; Christina H Ruhlmann; Franziska Jahn; Lee Schwartzberg; Bernardo Rapoport; Cynthia N Rittenberg; Rebecca Clark-Snow Journal: Support Care Cancer Date: 2016-08-30 Impact factor: 3.603
Authors: Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2013-04-21 Impact factor: 3.603
Authors: Samantha C Sodergren; Ellen Copson; Alice White; Fabio Efficace; Mirjam Sprangers; Deborah Fitzsimmons; Andrew Bottomley; Colin D Johnson Journal: Target Oncol Date: 2016-06 Impact factor: 4.493
Authors: Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2013-07-11 Impact factor: 3.603